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ABSTRACT 
 
Purpose: Androgens may have a role in bladder carcinogenesis. We studied whether use of 5-alpha-
reductase inhibitors (5-ARIs) associates with bladder cancer (BCa)-specific mortality in a population-
based cohort of men with BCa. 
Materials and methods: The study cohort consists of 10,720 Finnish men with newly diagnosed 
BCa during 1997-2012, identified from national cancer registry. Median follow-up was 4.17 years 
after BCa diagnosis. 
Hazard ratios (HRs) and 95% confidence intervals (CI) for the risk of BCa death by 5-ARI use were 
analyzed using Cox regression adjusted for age, gender, co-morbidities, primary bladder cancer 
treatment and tumor extent at diagnosis. Lag time analyses were performed to assess long-term risk 
association. Simultaneous use of alpha-blockers was taken into account to estimate possible 
confounding by indication. 
Results: 5-ARI use before BCa diagnosis was associated with lowered risk of BCa death (HR 0.84, 
95% CI 0.73-0.97). The risk decrease became stronger along with years of use. Conversely, pre-
diagnostic use of alpha-blockers did not associate with BCa survival (HR 1.02, 95% CI 0.91-1.13).  
Similarly, use of 5-ARIs after the diagnosis was associated with decreased risk of BCa death (HR 
0.77, 95% CI 0.68-0.88). Again, the use of alpha-blockers did not associate with BCa survival (HR 
0.98, 95% CI 0.90-1.07). The risk decrease by 5-ARI use persisted with up to five years’ time lag. 
 Conclusions: 5-ARI users have improved disease-specific survival after BCa diagnosis compared to 
non-users, whereas alpha-blocker use does not associate with the survival. This supports the benefits 
of 5-alpha-reductase inhibition in bladder cancer.  
 
 
 
INTRODUCTION 
 
Urothelial bladder cancer is the sixth most common cancer type among men worldwide.1 More than 
70-80% of bladder cancers are superficial and treatable with transurethral resection (TURB), often 
combined with intravesical instillations. In 25% of cases bladder cancer infiltrates the muscle layer 
of the bladder wall. In these cases, a radical cystectomy combined with chemotherapy is often needed. 
Less than 10% of bladder cancers have already metastasized at diagnosis and are palliatively treated 
with chemotherapy and radiation. Tumors are also classified by cytology into low-grade or high-
grade, high-grade being the most malignant and potentially invasive.2 
 
Superficial low-grade bladder cancer often recurs, but disease-specific survival is excellent. This is 
not the case for muscle-infiltrating invasive cancer, which has five-year survival rate of 50-65%. 
Metastatic disease is still incurable and the life expectancy is less than 16 months.3 
 
The prevalence of bladder cancer is higher among men than women. The reason for the gender 
difference is unknown but androgens have been proposed to have an impact on urothelial 
carcinogenesis; androgen receptor signaling may promote growth of urothelial cancer cells.4 
Importance of androgens in urothelial bladder cancer was supported by a recent study reporting 
reduced incidence of bladder cancer in men using 5α-reductase inhibitors (5-ARIs) finasteride or 
dutasteride compared to the non-users.5 These drugs inhibit conversion of testosterone to 
dihydrotestosterone (DHT), a more potent activator of androgen signalling. The enzyme 5α-reductase 
is expressed mainly in the prostate, and 5-ARIs are mainly used for management of benign prostatic 
hyperplasia. However, 5α-reductase is also expressed by urothelial cancer cells, and DHT has been 
found to affect their growth.6,7 Therefore it can be presumed that use of 5-ARIs would have benefits 
in bladder cancer patients, but currently no published studies have examined how 5-ARIs may affect 
bladder cancer prognosis.  
 
We performed a population-based cohort study in Finland to estimate whether use of 5-ARIs is 
associated with bladder cancer prognosis, with the hypothesis that the prognosis is better among 5-
ARI users. As 5-ARIs are used to treat benign prostate hyperplasia (BPH) and lower urinary tract 
symptoms (LUTS) caused by BPH, 5-ARI users are more likely than non-users to be under urologist’s 
supervision, creating possible selection bias. To assess and control for this bias we additionally 
analyzed the risk association for alpha-blockers that are used partly for the same indications. 
 
 
 
 
  
MATERIALS AND METHODS 
 
Study population 
We collected all urothelial cancers of the bladder diagnosed in Finland during 1997-2012 from the 
comprehensive national Finnish Cancer Registry (FCR) based on ICD-10 codes (C67.0-C67.9).8 A 
total of 10,720 men were included in the study. The available data included date of cancer diagnosis, 
tumor extent (localized, locally advanced or metastatic), primary treatment (surgery versus other), 
the date and the cause of death. The FCR data were linked to the information from Care Register for 
Health Care (HILMO) based on personal unique identification number. HILMO data contained 
diagnoses and procedures recorded at hospital contacts in Finnish healthcare units in 1997-2012.9 
Data on HILMO was used to evaluate comorbidities (diabetes, hypercholesterolemia and 
hypertension) and to obtain information on timing and number of endoscopic and open surgical 
procedures for bladder cancer after diagnosis. Surgical procedures were identified using procedure 
codes KCD02, KCD05, KCD32, KCC00, KCC10 and KCC20. (Supplement table 1) 
 
Information on medication use 
The study cohort was linked to national prescription database managed by Social Insurance Institution 
of Finland (SII) to obtain data on 5-ARI (finasteride, dutasteride) medication purchases in 1997-2012. 
Additionally, data on cholesterol-lowering, antihypertensive and antidiabetic drug purchases was also 
collected. The database provided detailed information on each medication purchase, including the 
date of purchase, ATC-coding, package size and dosage.  
 
As part of national health insurance available to all Finnish citizens, SII partly covers costs for 
physician prescribed drug purchases.10 The reimbursement is available to all Finnish citizens.  Each 
reimbursed prescription purchase is recorded, regardless of the rate of SII cost coverage. Alpha-
blockers and 5-ARIs are available in Finland solely by prescription, thus comprehensively recorded 
by the database. The only exception is 1 mg finasteride used for treatment of androgenetic alopecia. 
Also, over-the-counter medications and medications used during inpatient are not recorded by the 
database.  
 
Statistical analysis 
Age distribution, tumor and treatment characteristics and the prevalence of co-morbidities were 
compared by 5-ARI use before and after bladder cancer diagnosis. We used Chi-square test to test for 
statistical significance of difference in categorical variables and Mann-Whitney U-test for non-
categorical variables. Analyses on pre- and post-diagnostic use were made in separate models. 
 
Logistic regression was used to calculate odds ratios (OR) and 95% confidence intervals (95% CI) 
for the risk of having more than two or more than five TURBs after bladder cancer diagnosis.  Logistic 
regression model was adjusted for age and co-morbidities. 
 
Hazard ratios (HRs) and 95% CIs for the risk of bladder cancer death were analyzed using Cox 
regression adjusted for age, gender, co-morbidities, primary bladder cancer treatment (surgery vs. 
other) and tumor extent at diagnosis (localized vs metastatic). The unknown tumor extent was 
included in the analysis as one category. The time-metric was years and months since bladder cancer 
diagnosis. Follow-up continued until death, emigration or common closing date 31.Dec. 2012, 
whichever came first.  
 
Medication use was divided to pre-diagnostic and post-diagnostic usage according to the year of drug 
purchases. Usage at the year of diagnosis was included in post-diagnostic use. Users of 5-ARIs were 
stratified into two subgroups by median number of 5-ARI doses used/year. Similar stratifications 
were done for alpha-blockers. 
 
Pre-diagnostic 5-ARI use was analyzed as time-fixed variable taking into account all usage occurring 
between 1997 and the year of diagnosis. Post-diagnostic 5-ARI use was analyzed as time-dependent 
variable, where user status and annual dosage were updated separately for each follow-up year based 
on the annual recorded purchases. Alpha-blocker use and 5-ARI use were entered into the regression 
model together to take into account simultaneous usage. 
 
Long-term risk associations were evaluated in lag-time analyses where medication use was lagged 
forward in follow-up time. In 3-year lag-time analysis we estimated effects of 5-ARI use occurring 
three years earlier; e.g. for end-points occurring in 2005 we used 5-ARI exposure in 2002. 
All statistical p-values are two-sided. All analyses were performed using IBM SPSS Statistic 
software. 
 
 
 
 
 
 
 
 
 
 
  
RESULTS 
 
Population characteristics  
 
In the study population of 10,720 men, the median follow-up was 4.17 years after bladder cancer 
diagnosis. In total 6,100 (56.9%) participants died during the follow-up. The number of deaths caused 
by bladder cancer was 2,332 (21.8%).  
 
Drug users before the diagnosis 
 
Both 5-ARI and alpha-blocker users were generally slightly older than non-users. Median age among 
5-ARI was two years higher (78 years) compared to alpha-blocker users. There was no statistically 
significant difference in the proportions of all-cause or bladder cancer deaths between 5-ARI and 
alpha-blocker users. However, when compared to non-users, both 5-ARI and alpha-blocker users had 
significantly lower all-cause and bladder cancer specific mortalities. At diagnosis, 5-ARI users had 
more often metastatic bladder cancers than alpha-blocker users (14.5% vs. 13.0%). However, there 
were more localized bladder cancers among alpha-blocker than 5-ARI users (60.8 vs. 59.0). (Table 
1) 
 
TABLE 1. Population characteristics 
  
Non-users 5-ARI users alpha-blocker users 
  
Pre-
diagnosis* 
Post-
diagnosis* 
Pre-
diagnosis 
Post-
diagnosis 
N of participants 5090 1328 1880 2353 4250 
Median age (IQR) at diagnosis 70 (61-78) 78 (72-83) 75 (68-81) 76 (70-82) 74 (66-80) 
Median (IQR) follow-up time 3,75 
(1,25-
8.08) 
3.25 (1.5-
5.75) 
5.17 (2.5-
9.3) 
3.25 (1.5-
6.17) 
5.1 (2.4-
9.1) 
N (%) deaths 3088 
(60.7) 
725 (54.6) 856 (45.5) 1286 
(54.7) 
2176 
(51.2) 
Overall mortality 607/1,000 546/1,000 455/1,000 547/1,000 512/1,000 
N (%) bladder cancer deaths 1246 
(40.3) 
288 (21.7) 266 (14.1) 514 (21.8) 761 (17.9) 
Overall bladder cancer specific 
mortality 
245/1,000 217/1,000 141/1,000 218/1,000 179/1,000 
Tumor extent; n (%) 
 
    
Localized 3,176 
(60.4) 
784 (59.0) 1257 
(66.9) 
1430 
(60.8) 
2782 
(65.5) 
Metastatic 698 (13.3) 193 (14.5) 162 (8.6) 306 (13.0) 404 (9.5) 
Unknown 1,388 
(26.4) 
351 (26.4) 461 (24.5) 617 (26.2) 1064 
(25.0) 
P-value Ref 0.01 0.00 0.19 0.12 
Median (IQR) number of surgical 
procedures 
2 (1-9) 2 (1-9) 1 (1-7) 2 (1-9) 2 (1-8) 
P-value Ref 0.00 0.00 0.00 0.04 
Median (IQR) Charlson co-morbidity 
index 
4 (3-4) 4 (3-4) 4 (3-4) 4 (3-4) 4 (3-4) 
P-value Ref 0.79 0.21 0.17 0.56 
N (%) of men treated with 
cystectomy 
749 (14.7) 141 (10.6) 127 (6.8) 297 (12.6) 398 (9.4) 
P-value Ref 0.06 0.00 0.51 0.00 
N (%) of men receiving radiation 
therapy 
616 (12.1) 167 (12.6) 158 (6.4) 292 (12.4) 488 (11.5) 
P-value Ref 0.00 0.00 0.00 0.04 
N (%) of men receiving 
chemotherapy 
1021 
(20.1) 
274 (20.6) 378 (20.1) 487 (20.7) 968 (22.8) 
P-value Ref 0.01 0.13 0.00 0.50 
 
* Simultaneous use of 5-ARIs and alpha-blockers: N=897 (67.5 % of 5-ARI users) before BCa 
diagnosis, N=1,389 (73.9%) after it 
 
 
There was no statistically significant difference between 5-ARI and alpha-blocker users in median 
Charlson co-morbidity index or in the median number of surgical procedures after bladder cancer 
diagnosis. Alpha-blocker users were treated more often with cystoprostatectomy when compared to 
5-ARI users (12.6% vs. 10.6%). However, there was no significant difference between 5-ARI and 
alpha-blocker users in the proportion of men receiving radiation and chemotherapy. (Table 1) 
 Drug users after the diagnosis 
l 
For post-diagnostic use, both 5-ARI and alpha-blocker users were nearly the same age, 5-ARI users 
being a year older (75 years) than alpha-blocker users. All-cause mortality was lower between 5-ARI 
and alpha-blocker users (45.5% and 51.2%, respectively) as was bladder cancer specific morality 
(14.1% and 17.9%). However, when compared to non-users, both 5-ARI and alpha-blocker users had 
lower all-cause and bladder cancer specific mortalities. 5-ARI users tended to have more localized 
tumors at diagnosis than alpha-blocker users (66.9% vs. 65.5%), whereas metastatic tumor extent was 
more common among alpha-blocker users (9.5% vs. 8.6%). (Table 1) 
 
 
5-ARI users had undergone less surgical procedures than alpha-blocker users (1 vs. 2). Additionally, 
5-ARI users had less cystectomies (6.8% vs. 9.4%), radiation (8.4% vs. 11.5%) and chemotherapies 
(20.1% vs. 22.8%) than alpha-blocker users. There was no statistically significant difference between 
5-ARI and alpha-blocker users in Charlson co-morbidity index. (Table 1) 
 
Bladder cancer survival by 5-ARI and alpha-blocker use before the diagnosis 
Figure 1. Bladder cancer-specific survival by 5alpha-reductase inhibitor and alpha-blocker use 
before bladder cancer diagnosis 
 
a) 5-alpha-reductase inhibitors 
 
 
 
 
N of 
men at 
risk 
10,720 4,772 1,974 571 
 
 
Compared to non-users, 5-ARI-use before bladder cancer diagnosis was associated with lowered risk 
of bladder cancer death in the multi-variable adjusted analysis (HR 0.85, 95% CI 0.74-0.97) (Table 
2, Figure 1a). The risk decrease did not clearly depend on the annual dose but became stronger along 
with years of use; in stratified analysis the risk decrease was significant only after 3 years of use. 
  
Conversely, pre-diagnostic use of alpha-blockers was not associated with bladder cancer survival 
(HR 1.02, 95% CI 0.92-1.14) (Table 2, Figure 1b). Again, the risk association did not depend on the 
annual dose or the duration of use.  
b) alpha-blockers 
 
 
 
 
TABLE 2. Risk of bladder cancer death by use of 5-ARIs and alpha-blockers before and after the 
diagnosis. Study population of 10,720 Finnish men diagnosed with bladder cancer during 1997-
2012. 
 
 
Pre-diagnostic use  
5-ARI users 
 
Alpha-blocker users 
Medicatio
n use 
N of 
participants/death
s 
HR (95% 
CI)age 
adjusted 
HR (95% 
CI) 
mutlivariabl
e adjusted 
 
N of 
participants/death
s 
HR 
(95% 
CI)age 
adjusted 
HR (95% 
CI) 
mutlivariabl
e adjusted 
Non-users 
 
Ref Ref 
  
Ref Ref 
Any use 1328/288 0.89 
(0.78-
1.02) 
0.85 
(0.74-
0.97) 
 
2353/514 0.94 
(0.85-
1.05) 
1.02 
(0.92-
1.14) 
Intensity of use: Median 228 
doses/year 
 
 
Median 135 doses/year 
 
 
Median or 
below 
664/152 0.96 
(0.81-
1,148) 
0.87 
(0.73-
1.04) 
 
1173/236 0.87 
(0.76-
1.00) 
0.92 
(0.80-
1.06) 
Above 
median 
664/136 0.82 
(0.68-
0.98) 
0.82 
(0.69-
0.99) 
 
1180/278 1.03 
(0.90-
1.18) 
1.14 
(0.99-
1.30) 
Duration of use: 
 
Median 2 years 
 
  
Median 2 years 
 
Median or 
below 
741/177 1.01 
(0.86-
1.19) 
0.92 
(0.78-
1.08) 
 
1414/316 0.97 
(0.86-
1.10) 
1.01 
(0.89-
1.14) 
Above 
median 
587/111 0.75 
(0.62-
0.92) 
0.76 
(0.62-
0.93) 
 
939/198 0.90 
(0.77-
1.06) 
1.05 
(0.89-
1.23)         
Post-diagnostic use  
5-ARI users 
 
Alpha-blocker users 
Medicatio
n use 
N of 
participants/death
s 
HR (95% 
CI)age 
adjusted 
HR (95% 
CI) 
mutlivariabl
e adjusted 
 
N of 
participants/death
s 
HR 
(95% 
CI)age 
adjusted 
HR (95% 
CI) 
mutlivariabl
e adjusted 
Non-users 
 
Ref Ref 
  
Ref Ref 
Any use 1880/266 0.73 
(0.64-
0.83) 
0.78 
(0.68-
0.89) 
 
4250/761 0.93 
(0.85-
1.02) 
0.96 
(0.88-
1.06) 
Intensity of use: 
 
Median 225 
doses/year 
  
Median 145 
doses/year 
 
Median or 
below 
943/172 0.98 
(0.83-
1.15) 
0.93 
(0.79-
1.09) 
 
2126/463 1.09 
(0.98-
1.21) 
1.04 
(0.94-
1.16) 
Above 
median 
937/94 0.51 
(0.41-
0.63) 
0.61 
(0.50-
0.75) 
 
2124/298 0.76 
(0.66-
0.86) 
0.86 
(0.76-
0.98) 
Duration of use: 
 
Median 2 years 
 
  
Median 1 year 
 
Median or 
below 
1281/232 0.745 
(0.65-
0.86) 
0.78 
(0.68-
0.90) 
 
2176/512 0.92 
(0.83-
1.02) 
0.92 
(0.83-
1.01) 
Above 
median 
599/34 0.61 
(0.43-
0.87) 
0.73 
(0.51-
1.04) 
 
2074/249 0.96 
(0.82-
1.12) 
1.13 
(0.97-
1.32) 
 
 
 
Bladder cancer survival by 5-ARI and alpha-blocker use after the diagnosis 
 
The use of 5-ARIs after bladder cancer diagnosis was associated with decreased risk of cancer-
specific death in the multi-variable adjusted analysis (HR 0.77, 95% CI 0.68-0.88) (Table 2). Also 
for post-diagnostic use the risk decrease was dose-dependent, in inverse correlation with yearly dose 
of 5-ARI use. 
 
Again, use of alpha-blockers did not relate to bladder cancer survival (HR 0.98, 95% CI 0.90-1.07) 
(Table 2). However, in high-dose (more than 210mg in total) use alpha-blockers were also associated 
with lowered bladder cancer mortality compared to non-users. Nevertheless, 5-ARI users had greater 
risk reduction than alpha-blocker users especially after multivariable adjustment.  
 
Lag-time analyses 
 
Decreased risk of bladder cancer death became statistically non-significant within three years’ lag 
time, although the risk estimate was lowered even with time lag of five years (Table 3). 
 
TABLE 3. Long-term association between 5-ARI use and risk of bladder cancer death. Study 
population of 10,720 Finnish men diagnosed with bladder cancer during 1997-2012. 
 
 Lag time: 
 None 1 yr 3 yrs 5 yrs 
 HR (95% CI) multivariable adjusted 
HR (95% CI) mutlivariable 
adjusted 
HR (95% CI) 
mutlivariable adjusted 
HR (95% CI) 
mutlivariable adjusted 
5-ARI use      
None Ref Ref Ref Ref 
Any 0.78 (0.68-0.89) 0.75 (0.65-0.86) 0.86 (0.73-1.01) 
0.87 (0.71-
1.05) 
 
 
 
The association between 5-ARI and alpha-blocker use and number of TURBs 
 
Among endoscopically treated patients both 5-ARI and alpha-blocker use were associated with a 
lower risk of having multiple TURB procedures after bladder cancer diagnosis compared to the non-
users (Table 4). The association was statistically significant only among alpha-blocker users, but 
similar risk estimates were observed also in 5-ARI users. 
 
TABLE 4. Risk of having multiple TURBs after diagnosis by 5-ARI and alpha-blocker use. 
 
Risk of having multiple TURB:s after diagnosis by 5-ARI and alpha-blocker use 
 5-ARIs  alpha-blockers 
Number of 
TURBs 
OR (95% CI) 
age adjusted 
OR (95% CI) 
mutlivariable adjusted 
 OR (95% CI) 
age adjusted 
OR (95% CI) 
mutlivariable adjusted 
2 or more 0.89 (0.74-1.07) 0.89 (0.74-1.07)  0.84 (0.73-0.98) 0.84 (0.72-0.97) 
5 or more 0.82 (0.59-1.16) 0.82 (0.58-1.16)  0.70 (0.54-0.92) 0.70 (0.54-0.91) 
 
 
 
  
DISCUSSION 
 
 
Men who use 5-ARIs had a lower risk for bladder cancer death compared to the non-users. This risk 
difference was not observed among the alpha-blocker users, even after adjustment for co-morbidities 
and other background variables. Indications for use of these drug groups overlap, but only 5-ARIs 
affect androgen metabolism. Thus our results support role of androgens in bladder cancer progression.  
 
This is the first study that clarifies the association between use of 5ARIs targeting androgen 
metabolism and bladder cancer survival. In a prior study the use of 5-ARIs was associated with a 
lowered risk for bladder cancer.5 These findings have been subsequently supported by a case-control 
study reporting lowered risk of bladder cancer in Taiwanese men using finasteride and a cohort study 
demonstrating decreased bladder cancer risk among men using 5-ARIs or androgen deprivation 
therapy for prostate cancer in a cohort of 228 Japanese men.7,11 The results of our study are in line 
with the previous studies regarding potential beneficial effects of 5-ARI use in men with bladder 
cancer. However, to our knowledge this is the first study to suggest beneficial effects of 5-ARI use 
and role of androgens in bladder cancer progression. Interestingly, also androgen deprivation therapy 
for prostate cancer has been linked to lowered risk of BCa recurrence further supporting the role of 
androgens in BCa.12  
 
The risk association with bladder cancer death among 5-ARI users depended on annual dose and 
cumulative duration of use. This suggests a causal association. However, non-causal explanations 
must be considered as well. 
 
The indication for 5-ARI use in our study is symptomatic benign prostatic hyperplasia. Our data did 
not cover 5-ARI usage for male pattern baldness. Men with lower urinary tract symptoms (LUTS) 
undergo urological examination more often than men without such symptoms. Therefore, bladder 
tumors could be detected earlier and at more curable phase in such men, generating lead time bias. 
This bias was evaluated by analyzing also alpha-blockers, drug group with similar indications for use, 
thus affected by the same bias, but with a completely different mechanism of action. The risk decrease 
was observed only in 5-ARI users, strongly suggesting that lead time bias does not explain the 
observed risk difference. Further, lead time bias would presumably mean less TURBs required in 5-
ARI and alpha-blocker users compared to non-users. A significantly lower risk of undergoing 
multiple TURBs was observed only in alpha-blocker users compared to non-users, again arguing 
against lead time bias in 5-ARI users. 
 
Another possible non-causal explanation could be more efficient treatment of bladder cancer in men 
using 5-ARIs. Such men could be presumed to be more generally fit and more often suitable for 
cystectomy. However, 5-ARI users were less often managed with cystectomy which further argues 
against healthy user bias.  
 
The strength of our study is the ability to compare bladder cancer survival between 5-ARI users and 
alpha-blocker users. Alpha-blockers and 5-ARIs have completely different mechanisms of action, yet 
they are used often with similar indications and therefore these comparisons allowed evaluation the 
impact of selection bias between users and non-users. Interestingly, the survival benefit was observed 
only among men using 5-ARIs, supporting a causal association.  
 
The data for the study was collected from nation-wide databases that provided us accurate information 
on drug purchases and bladder cancer deaths. The exact drug use history enabled us to evaluate 
separately medication use before and after bladder cancer diagnosis and to evaluate the dose- and 
time-related dependence on the risk of bladder cancer death, as well as simultaneous use of 5ARIs 
and alpha-blockers.  
Finasteride treatment of androgenetic alopecia was not recorded by SII, causing bias towards the null. 
However, this does not interfere with our conclusion of improved BCa survival among 5-ARI users. 
As our study is a retrospective comparison and 5-ARI use was not randomized, confounding due to 
background factors, such as socioeconomic inequality, could have affected observed survival 
differences. Information on intravesical therapies was not available in the national database. On the 
other hand, the lack of data concerned the alpha-blocker group as well, thus not affecting comparisons 
between 5-ARI users and alpha-blocker users. We had no information on the participants’ lifestyle-
related risk factors, such as tobacco smoking, nutrition or physical activity, that may have an impact 
on the prognosis of cancer. These factors may differ between drug users and non-users. However, the 
bias caused by life style choices is not related to the amount of drug used, therefore the dose-
dependent risk trends seen for 5-ARI use are likely related to the direct effect of 5-ARIs on bladder 
cancer progression.  
 
 
 
 
 
 
 
 
 
 
CONCLUSIONS 
 
This is the first study estimating the role of 5-ARI use in the prognosis of bladder cancer. 5-ARI users 
have better disease-specific survival after bladder cancer diagnosis when compared to non-users. 
Similar risk associations were not observed in users of alpha-blockers. Our study supports the role of 
androgens in the progression of bladder cancer. If confirmed in further studies, 5-alpha-reductase 
inhibition may prove to be a viable strategy to improve bladder cancer outcomes  
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 Supplement table 1. Explanations of procedure codes. 
Procedure codes Explanation 
KCC00 Cystectomy 
KCC10 cystoprostatectomy 
KCC20 Cystroprostatectomy plus removal of urethra 
KCD02 TURB (transurethral resection of bladder tumor) 
KCD05 Endoscopic removal of bladder tumor 
KCD32 Endoscopic laser ablation of bladder tumor 
 
 
 
Supplement table 2. Risk for BCa death by tumor extent. Multivariable adjusted analysis. 
Pre-diagnostic use Localized Metastatic Unknown 
5-ARIs 0.98 (0.79-1.21) 0.86 (0.69-1.07) 0.62 (0.45-0.85) 
Alpha-blockers 1.09 (0.92-1.29) 0.89 (0.76-1.04) 0.99 (0.79-1.24) 
        
Post-diagnostic use       
5-ARIs 0.74 (0.60-0.91) 1.02 (0.82-1.26) 0.61 (0.45-0.83) 
Alpha-blockers 1.07 (0.93-1.23) 0.89 (0.76-1.04) 0.89 (0.74-1.08) 
 
